Regeneron Pharmaceuticals Inc (REGN)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013603)
◆英語タイトル:Regeneron Pharmaceuticals Inc (REGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013603
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:105
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥55,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥82,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Regeneron Pharmaceuticals Inc (Regeneron) is a biopharmaceutical company which discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company provides products for treating eye diseases, high low-density lipoprotein (LDL) cholesterol, a rare inflammatory condition, rheumatoid arthritis and metastatic colorectal cancer. It develops products based on its VelociSuite technology platforms, which include VelociGene, VelocImmune, VelociMouse, VelociMab and other related technologies. Regeneron is also developing various product candidates in clinical development for treating asthma, pain, cancer, atopic dermatitis and infectious diseases. It has subsidiaries in Belgium, Spain, the Netherlands, the US and the UK. Regeneron is headquartered in Tarrytown, NewYork, the US.

Regeneron Pharmaceuticals Inc (REGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 14
Private Equity 15
TRC Capital To Acquire 1.06% Stake In Regeneron Pharma For US$161 Million 15
Partnerships 16
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 16
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority for Infectious Diseases 17
Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 18
Inovio Pharma and Regeneron Pharma Enter into Agreement 19
Indivumed Enters into Agreement with Regeneron Pharma 20
Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 21
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 23
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 24
Bayer Enters into Co-Development Agreement with Regeneron Pharma 25
Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 26
Regeneron Pharma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 27
Regeneron Pharma Enters into Development Agreement with BARDA 28
Regeneron Pharma Enters into Co-Development Agreement with Sanofi 29
Regeneron Pharma Amends Co-Development Agreement with Sanofi 31
Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 32
Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 33
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 34
Licensing Agreements 36
Neovii Pharmaceuticals Enters into Licenses Agreement with Regeneron 36
Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 37
Regeneron Pharma Enters into Licensing Agreement with MedImmune 39
Regeneron Pharma Enters into Licensing Agreement with Adicet Bio 40
Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 41
Debt Offering 42
Regeneron Pharma Completes Private Placement Of 1.875% Convertible Senior Notes Due 2016 For US$400 Million 42
Regeneron Pharmaceuticals Inc – Key Competitors 43
Regeneron Pharmaceuticals Inc – Key Employees 44
Regeneron Pharmaceuticals Inc – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 48
Financial Announcements 48
Nov 08, 2017: Regeneron Reports Third Quarter 2017 Financial and Operating Results 48
Aug 03, 2017: Regeneron Reports Second Quarter 2017 Financial and Operating Results 51
May 04, 2017: Regeneron Reports First Quarter 2017 Financial And Operating Results 54
Feb 09, 2017: Regeneron Reports Fourth Quarter And Full Year 2016 Financial And Operating Results 57
Nov 04, 2016: Regeneron Reports Third Quarter 2016 Financial and Operating Results 61
Aug 04, 2016: Regeneron Reports Second Quarter 2016 Financial and Operating Results 64
May 05, 2016: Regeneron Reports First Quarter 2016 Financial and Operating Results 67
Feb 09, 2016: Regeneron Reports Fourth Quarter and Full Year 2015 Financial and Operating Results 70
Corporate Communications 73
Jan 31, 2017: Tony Coles, M.D., Elected To Regeneron Board Of Directors 73
Sep 12, 2016: Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors 74
Legal and Regulatory 75
Jul 28, 2017: U.S. Court of Appeals for the Federal Circuit Affirms Merus’ Inequitable Conduct Claim Against Regeneron 75
Feb 02, 2016: Kymab Succeeds in Revoking Regeneron’s UK VelocImmune Patents 76
Government and Public Interest 77
Mar 22, 2017: U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World’s Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis 77
May 26, 2016: Regeneron Selected by Society for Science & the Public as New Sponsor of the Science Talent Search 79
Product News 81
05/24/2016: New Cholesterol Treatment Now Available for Canadians 81
05/06/2016: Innovative cholesterol-lowering treatment, Praluent (alirocumab), approved by NICE for people with raised cholesterol levels who are at significantly high risk of a heart attack or stroke 82
04/25/2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection 84
02/08/2017: Appeals Court Grants Stay of Permanent Injunction for Praluent (alirocumab) During Appeals Process 85
Product Approvals 86
Jul 05, 2016: Regeneron and Sanofi Announce Approval of Praluent (alirocumab) for the Treatment of Hypercholesterolemia in Japan 86
Jun 22, 2016: NICE Green Lights Cholesterol-Lowering Treatment Praluent (alirocumab) For NHS Funding 88
Feb 08, 2016: NICE issues draft guidance on alirocumab for lipid disorder 90
Clinical Trials 91
Jun 11, 2017: Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent (alirocumab) in Individuals with Diabetes and Hypercholesterolemia 91
Jun 04, 2017: Regeneron And Sanofi Present Positive Study Results For Investigational PD-1 Antibody REGN2810 At American Society Of Clinical Oncology (Asco) Annual Meeting 93
Mar 07, 2017: Regeneron and Sanofi to Present New Phase 3 Praluent (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions 94
Nov 17, 2016: Regeneron and Sanofi Announce Praluent (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis 96
Nov 11, 2016: Regeneron and Sanofi to Present Data from Phase 3 Praluent (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016 97
Aug 29, 2016: Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016 99
Mar 30, 2016: Regeneron and Sanofi to Present Phase 3 Praluent (alirocumab) Injection Clinical Trial Data at ACC.16 101
Mar 23, 2016: Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy 103
Appendix 105
Methodology 105
About GlobalData 105
Contact Us 105
Disclaimer 105

List of Tables
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Regeneron Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 14
TRC Capital To Acquire 1.06% Stake In Regeneron Pharma For US$161 Million 15
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 16
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority for Infectious Diseases 17
Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 18
Inovio Pharma and Regeneron Pharma Enter into Agreement 19
Indivumed Enters into Agreement with Regeneron Pharma 20
Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 21
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 23
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 24
Bayer Enters into Co-Development Agreement with Regeneron Pharma 25
Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 26
Regeneron Pharma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 27
Regeneron Pharma Enters into Development Agreement with BARDA 28
Regeneron Pharma Enters into Co-Development Agreement with Sanofi 29
Regeneron Pharma Amends Co-Development Agreement with Sanofi 31
Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 32
Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 33
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 34
Neovii Pharmaceuticals Enters into Licenses Agreement with Regeneron 36
Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 37
Regeneron Pharma Enters into Licensing Agreement with MedImmune 39
Regeneron Pharma Enters into Licensing Agreement with Adicet Bio 40
Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 41
Regeneron Pharma Completes Private Placement Of 1.875% Convertible Senior Notes Due 2016 For US$400 Million 42
Regeneron Pharmaceuticals Inc, Key Competitors 43
Regeneron Pharmaceuticals Inc, Key Employees 44
Regeneron Pharmaceuticals Inc, Other Locations 46
Regeneron Pharmaceuticals Inc, Subsidiaries 46

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Regeneron Pharmaceuticals Inc (REGN)-製薬・医療分野:企業M&A・提携分析(Regeneron Pharmaceuticals Inc (REGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆